Pharmaceutical interventions for obesity: a public health perspective

被引:20
作者
Caveney, E. [1 ]
Caveney, B. J. [2 ]
Somaratne, R. [1 ]
Turner, J. R. [1 ]
Gourgiotis, L. [1 ]
机构
[1] Quintiles, Morrisville, NC 27560 USA
[2] Duke Univ, Med Ctr, Dept Occupat Med, Durham, NC USA
关键词
antiobesity drug; behavioural factors; clinical trial; cost-effectiveness; medicines management; obesity; obesity therapy; pathophysiological sequelae of obesity; pharmaceutical interventions; public health; regulatory guidance;
D O I
10.1111/j.1463-1326.2010.01353.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of obesity, a major risk factor for many chronic diseases, has risen in most developed countries over the past several decades. The economic burden for both public and private health care systems is substantial. Although certain non-pharmaceutical interventions have been proven efficacious in specific populations, the lack of scalability has caused many of these programmes to fail in sustainably decreasing the percent of patients who are overweight or obese. The benefits of other interventions, such as pharmaceutical agents, medical devices and surgery, should therefore be carefully considered: this article focuses on the first of these strategies. Various pharmaceutical products have been plagued with safety concerns or patient non-adherence because of unpleasant side effects. Therefore, the need for additional antiobesity drugs that are both safe and effective is considerable. This article discusses the regulatory landscape for the development of new antiobesity compounds in the United States and Europe and considers the ramifications of greater or lesser regulatory burdens.
引用
收藏
页码:490 / 497
页数:8
相关论文
共 28 条
[1]  
Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[2]  
[Anonymous], GUID IND DEV PROD WE
[3]  
[Anonymous], 311 WHO
[4]  
[Anonymous], 7 REPORT JOINT NATL
[5]  
[Anonymous], 2006, 10 Things you need to know about obesity
[6]  
[Anonymous], SCREEN OB AD REC RAT
[7]   Coronary Heart Disease and Body Fat Distribution [J].
Canoy, Dexter .
CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (02) :125-133
[8]  
CAVENEY E, 2010, J CLIN STUD JAN, P34
[9]  
DURHAM TA, 2008, INTRO STAT PHARM CLI
[10]  
*EMA, GUID CLIN EV MED PR